PROPHASE LABS INC (PRPH)
US74345W1080 - Common Stock
Taking everything into account, PRPH scores 3 out of 10 in our fundamental rating. PRPH was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PRPH have multiple concerns. PRPH is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PRPH has reported negative net income.
PRPH had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PRPH reported negative net income in multiple years.
In the past 5 years PRPH reported 4 times negative operating cash flow.
1.2 Ratios
PRPH has a Return On Assets of -18.25%. This is in the better half of the industry: PRPH outperforms 65.13% of its industry peers.
PRPH's Return On Equity of -33.98% is fine compared to the rest of the industry. PRPH outperforms 67.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.25% | ||
| ROE | -33.98% | ||
| ROIC | N/A |
ROA(3y)3.3%
ROA(5y)-4.41%
ROE(3y)1.95%
ROE(5y)-8.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRPH's Gross Margin of 36.59% is in line compared to the rest of the industry. PRPH outperforms 54.36% of its industry peers.
In the last couple of years the Gross Margin of PRPH has remained more or less at the same level.
PRPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.87%
GM growth 5Y-0.03%
2. Health
2.1 Basic Checks
PRPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRPH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PRPH has more shares outstanding
Compared to 1 year ago, PRPH has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.30, we must say that PRPH is in the distress zone and has some risk of bankruptcy.
PRPH has a better Altman-Z score (1.30) than 61.54% of its industry peers.
PRPH has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.14, PRPH is in line with its industry, outperforming 46.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.3 |
ROIC/WACCN/A
WACC9.5%
2.3 Liquidity
PRPH has a Current Ratio of 2.28. This indicates that PRPH is financially healthy and has no problem in meeting its short term obligations.
PRPH's Current ratio of 2.28 is on the low side compared to the rest of the industry. PRPH is outperformed by 61.54% of its industry peers.
PRPH has a Quick Ratio of 2.10. This indicates that PRPH is financially healthy and has no problem in meeting its short term obligations.
PRPH's Quick ratio of 2.10 is in line compared to the rest of the industry. PRPH outperforms 41.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.1 |
3. Growth
3.1 Past
PRPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -196.08%.
PRPH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.81%.
Measured over the past years, PRPH shows a very strong growth in Revenue. The Revenue has been growing by 27.64% on average per year.
EPS 1Y (TTM)-196.08%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-325%
Revenue 1Y (TTM)-63.81%
Revenue growth 3Y45.2%
Revenue growth 5Y27.64%
Revenue growth Q2Q-83.96%
3.2 Future
Based on estimates for the next years, PRPH will show a very strong growth in Earnings Per Share. The EPS will grow by 59.74% on average per year.
PRPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 59.37% yearly.
EPS Next Y-61.33%
EPS Next 2Y59.74%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-57.34%
Revenue Next 2Y59.37%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRPH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PRPH's earnings are expected to grow with 59.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.74%
EPS Next 3YN/A
5. Dividend
5.1 Amount
PRPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROPHASE LABS INC
NASDAQ:PRPH (5/1/2024, 7:17:29 PM)
5.19
+0.58 (+12.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap93.68M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.25% | ||
| ROE | -33.98% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.59% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-196.08%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-61.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-63.81%
Revenue growth 3Y45.2%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y